Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome. [electronic resource]
Producer: 20190726Description: 777-780 p. digitalISSN:- 1433-0350
- Adolescent
- Antineoplastic Agents -- therapeutic use
- Brentuximab Vedotin
- Carcinoma, Embryonal -- complications
- Central Nervous System Neoplasms -- drug therapy
- Down Syndrome -- complications
- Female
- Humans
- Immunoconjugates
- Ki-1 Antigen -- metabolism
- Ki-67 Antigen -- metabolism
- Magnetic Resonance Imaging
- Octamer Transcription Factor-3 -- metabolism
- Retrospective Studies
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.